All In Biotech

Drug Trial Radar · NCT07747935

Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma

A Phase 1b, Open-Label, Investigator-Led Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Apr 1, 2028

Study completion Apr 1, 2028

Sponsor

Lead sponsor
ReBio PharmaIndustry
Sponsor type
Industry
First posted
Aug 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neoadjuvant RBP-01 in patients with primary uveal melanoma.

Conditions

  • Uveal Melanoma

Interventions

  • RBP-01Drug

    Each RBP-01 dose consists of a 5 µL intravitreal injection conjugating 250 µg of sotrastaurin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety eventsTime frame: From first dose until 6 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.